May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
Visual Acuity and OCT Outcomes in Patients Treated With Bevacizumab for Presumed Ocular Histoplasmosis Syndrome
Author Affiliations & Notes
  • O.Z. Plous
    Retina Associates of Kentucky, Lexington, KY
  • E.R. Thomas
    Retina Associates of Kentucky, Lexington, KY
  • J.W. Kitchens
    Retina Associates of Kentucky, Lexington, KY
  • T.W. Stone
    Retina Associates of Kentucky, Lexington, KY
  • R.D. Isernhagen
    Retina Associates of Kentucky, Lexington, KY
  • W.J. Wood
    Retina Associates of Kentucky, Lexington, KY
  • Footnotes
    Commercial Relationships  O.Z. Plous, None; E.R. Thomas, None; J.W. Kitchens, None; T.W. Stone, None; R.D. Isernhagen, None; W.J. Wood, None.
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 5186. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      O.Z. Plous, E.R. Thomas, J.W. Kitchens, T.W. Stone, R.D. Isernhagen, W.J. Wood; Visual Acuity and OCT Outcomes in Patients Treated With Bevacizumab for Presumed Ocular Histoplasmosis Syndrome . Invest. Ophthalmol. Vis. Sci. 2006;47(13):5186.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the safety and efficacy of intravitreal bevacizumab in the treatment of presumed ocular Histoplasmosis syndrome.

Methods: : A retrospective chart review was performed on the medical records of patients diagnosed with choroidal neovascularization secondary to presumed ocular Histoplasmosis syndrome treated with intravitreal bevacizumab.

Results: : Fifteen patients with choroidal nevoascularization secondary to presumed ocular Histoplasmosis syndrome were injected with bevacizumab intravitreally. Visual acuity and OCT characteristics were analyzed at baseline, as well as at one and three months post–injection (results to be presented). No adverse events occurred.

Conclusions: : Bevacizumab is a safe and possibly effective treatment for choroidal neovascularization secondary to presumed ocular Histoplasmosis syndrome.

Keywords: retina • choroid: neovascularization • pharmacology 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×